Cagrilintide and CagriSema Explained: The Amylin Analog Behind the Next GLP-1 Combination

"} comments at each figure. */}

Every metabolic peptide covered on this site so far, semaglutide, tirzepatide, retatrutide, survodutide, shares one thing in common: they all work, in whole or in part, through the incretin system, the GLP-1 receptor with or without GIP or glucagon layered on. Cagrilintide is different. It does not touch any of those receptors; it is an amylin analog, an engineered version of a separate pancreatic hormone that reaches satiety through its own signaling pathway. ^[3] That is why cagrilintide is not positioned as a replacement for semaglutide or tirzepatide, but as a partner to them, most visibly in CagriSema, the cagrilintide-semaglutide combination now in Phase 3 testing.

This guide is evidence-first and honest about where the evidence is still thin. Cagrilintide monotherapy has a completed Phase 2 trial, and CagriSema has completed Phase 3 REDEFINE trials with topline results reported, though the full peer-reviewed data are still emerging. Everything here reports what has been published or publicly disclosed; none of it is medical advice, and neither cagrilintide nor CagriSema is approved for human use.

Cagrilintide and CagriSema at a glance

What cagrilintide is: a hormone the GLP-1 class doesn't touch

Amylin is a hormone co-secreted with insulin from the pancreatic beta cell in response to a meal. Its job in normal physiology is to slow gastric emptying, promote satiety, and suppress glucagon, a set of effects that overlaps in outcome with GLP-1 but arrives through an entirely separate receptor system. ^[3] In obesity and longstanding type 2 diabetes, endogenous amylin signaling is reduced, part of the rationale for replacing it pharmacologically rather than only boosting the incretin side of the ledger.

Cagrilintide is a modified, long-acting version of amylin, engineered the same way the modern GLP-1 drugs were: a fatty-acid side chain that binds serum albumin and stretches a hormone that would otherwise last minutes in circulation into something dosable once a week. ^[1] The engineering approach is familiar; the receptor it targets is not.

The practical reason this distinction matters is additive potential. Because cagrilintide and the incretin drugs act on different receptors, combining them is a bet on two independent satiety signals stacking, rather than one receptor being pushed harder. ^[3] That is the entire thesis behind CagriSema.

What the cagrilintide Phase 2 trial showed

Before CagriSema existed as a combination, cagrilintide was tested alone. Its Phase 2 trial in adults with overweight or obesity, published in The Lancet, randomized participants to cagrilintide at several doses, placebo, and an active GLP-1 comparator (liraglutide 3.0 mg), the first approved GLP-1 drug for chronic weight management. ^[1] At the 4.5 mg dose, cagrilintide produced 10.8% mean weight loss at 26 weeks, ahead of both placebo and the liraglutide arm. ^[1]

That result mattered for two reasons. First, it established that amylin agonism alone, with no incretin receptor involved, could produce weight loss competitive with an approved GLP-1 drug, evidence that the mechanism is not a minor accessory to GLP-1 biology but a legitimate standalone lever. Second, it set up the obvious next question: what happens if you combine cagrilintide with a GLP-1 drug that works even better alone than liraglutide does. That question is what CagriSema was built to answer.

What CagriSema is: pairing two independent pathways

CagriSema is Novo Nordisk's fixed-ratio combination of cagrilintide and semaglutide in a single once-weekly subcutaneous injection. ^[2] The design logic is straightforward once you separate the two mechanisms: semaglutide brings the well-characterized GLP-1 effect (appetite suppression, slowed gastric emptying, improved glucose handling), and cagrilintide brings a second, independent satiety signal through the amylin receptor. Because the pathways are distinct, the combination is a bet on additive, not merely incremental, efficacy. ^[3]

This is a different kind of combination than the multi-receptor single molecules covered elsewhere on this site. Tirzepatide and retatrutide are single peptides engineered to activate multiple incretin receptors at once. CagriSema is two separate peptides, co-formulated and co-dosed. The distinction matters for reading the evidence: tirzepatide and retatrutide's multi-receptor effects come from one molecule's binding profile, while CagriSema's combined effect is, mechanistically, the sum of two established drug classes acting in the same patient at the same time.

The REDEFINE program: what Phase 3 has reported so far

CagriSema's confirmatory testing runs under Novo Nordisk's REDEFINE program, a set of Phase 3 trials studying the combination across populations: adults with obesity, adults with obesity and type 2 diabetes, and cardiovascular outcomes. ^[2] This is the stage where a combination has to hold up in larger, longer, more rigorous testing than the Phase 2 work that preceded it, and it is also the stage where CagriSema's story got more complicated than the earlier data suggested it would.

The honest framing here is a deliberate departure from how the retatrutide and tirzepatide Phase 2 stories read on this site. Cagrilintide's own Phase 2 data, and the early CagriSema disclosures that followed it, generated real excitement about a combination that might exceed anything in the incretin class alone. REDEFINE 1's topline result, approximately 20% mean weight loss at 68 weeks, still represents a large absolute effect, but it landed below the company's own pre-specified expectation, a reminder that a strong earlier signal does not guarantee a confirmatory Phase 3 trial reproduces it at the same magnitude. ^[2]

The fair answer to whether cagrilintide, or CagriSema, actually works: cagrilintide alone reached 10.8% mean weight loss in a completed, positive Phase 2 trial, and CagriSema's Phase 3 topline of approximately 20% confirms the combination produces meaningful weight loss, just not necessarily at the scale some earlier disclosures implied. ^{[1] [2]} Neither figure is a guarantee of any individual outcome; both are population means from controlled trials with their own inclusion criteria and durations.

Cagrilintide vs semaglutide

Cagrilintide and semaglutide are not competitors so much as two different levers, which is why they were combined rather than compared as substitutes. Semaglutide is the established single-receptor GLP-1 reference point, with 14.9% mean weight loss at 68 weeks in STEP 1 on the 2.4 mg dose. ^[4] Cagrilintide alone, over a shorter 26-week window, produced 10.8% mean weight loss on the 4.5 mg dose through an entirely different receptor. ^[1] The more useful question is not which is better but what adding cagrilintide to semaglutide does that semaglutide alone does not, which is the CagriSema question above. For semaglutide on its own, mechanism, STEP and SUSTAIN data, dosing, and sourcing, see the complete semaglutide guide.

Cagrilintide vs tirzepatide, retatrutide, and survodutide

None of these three share a receptor with cagrilintide, so each comparison is really a mechanism contrast rather than a head-to-head efficacy test.

Tirzepatide and retatrutide add receptors within the incretin family (GIP, then glucagon); survodutide swaps GIP for glucagon within that same family. Cagrilintide sits outside the family entirely, which is why comparing its monotherapy number against tirzepatide's or retatrutide's understates what it is for: it was designed to be added on top of an incretin drug, not to outcompete one alone. That is the CagriSema model, and so far it has only been tested with semaglutide. Any cagrilintide-plus-tirzepatide or cagrilintide-plus-retatrutide combination is a mechanistic hypothesis researchers discuss, not a result from a published trial. For the full pictures of each, see the complete retatrutide guide and retatrutide vs survodutide.

Side effects reported in trials

Cagrilintide and CagriSema's tolerability profile follows the same general shape as the rest of the class, dominated by gastrointestinal effects, with amylin agonism adding its own signature.

The gastrointestinal effects trace to the same underlying logic that applies across the GLP-1 class: both amylin and GLP-1 signaling slow gastric emptying as part of how they produce satiety, and that same slowing is what produces nausea when exposure rises too quickly. ^[3] That is why cagrilintide, like every compound on this site, is titrated gradually rather than started at target dose. Cagrilintide's monotherapy trial also reported injection-site reactions at a rate the study authors noted as a feature to watch, a finding not as prominent in the pure incretin compounds. ^[1]

Cagrilintide side effects: anxiety, mood, and hair loss claims

Online discussion of cagrilintide includes anecdotal reports of mood changes, anxiety, and hair thinning. None are established, trial-reported adverse effects specific to cagrilintide in the published Phase 2 data; the confirmed profile is the gastrointestinal and injection-site pattern described above. ^[1] Hair thinning is reported anecdotally across rapid-weight-loss protocols generally, GLP-1 included, and is more plausibly linked to the physiological stress of fast weight loss (telogen effluvium) than to any specific receptor mechanism. Anecdotal reports are not the same evidentiary tier as a controlled trial finding.

Cagrilintide and CagriSema dosing landscape

The recurring theme across every dosing table on this site applies here too: milligram figures are not comparable across compounds, because potency per milligram differs by molecule. What is comparable is the shared logic behind titration itself. Every compound in this table is escalated gradually because gastrointestinal tolerability tracks how fast exposure rises, not simply how high it eventually goes. These are trial-reported protocols, described here as information, not a dosing recommendation.

Other reported and investigational benefits

Beyond the headline weight-loss numbers, amylin biology carries a few additional angles worth understanding, some better supported than others.

The lean-mass claim deserves particular caution. It circulates widely in research communities as a reason to prefer amylin-containing regimens, on the logic that amylin's satiety mechanism does not overlap with pathways implicated in muscle catabolism during caloric restriction. That is a coherent hypothesis, not a demonstrated result specific to cagrilintide; treat it as an open research question rather than a settled benefit until dedicated body-composition data are published and reviewed.

Is cagrilintide, or CagriSema, right for your research

Cagrilintide and CagriSema sit at a different point on the maturity curve than the compounds covered elsewhere on this site. Semaglutide, tirzepatide, and retatrutide each have a completed, published Phase 2 dataset behind them. Cagrilintide has one completed Phase 2 monotherapy trial, and CagriSema's Phase 3 program is still delivering its full data set, with topline results that have already shown the combination does not simply repeat cagrilintide's early promise at face value. A genuinely novel mechanism paired with the least mature dataset on this site is exactly what makes it a frontier research question rather than a settled protocol.

Common mistakes when evaluating cagrilintide claims

• Treating cagrilintide as a stronger GLP-1 drug rather than a mechanistically separate one, which leads to comparing numbers across a receptor difference that matters.
• Reading topline sponsor disclosures as equivalent to peer-reviewed trial data, when the full published manuscripts are the evidence bar this site anchors every other compound to.
• Anchoring on cagrilintide-plus-tirzepatide or cagrilintide-plus-retatrutide as tested combinations. Only cagrilintide-plus-semaglutide, CagriSema, has a published trial.

For research and educational purposes only. Not medical advice. Trial figures describe published clinical studies and, where noted, sponsor-disclosed topline results that may not yet reflect a final peer-reviewed manuscript; cross-compound comparisons are drawn from separate trials, not head-to-head studies. Cagrilintide and CagriSema are investigational and are not approved for human use.